Cencora Authorizes $2 Billion Share Repurchase Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 52 minutes ago
0mins
Source: Newsfilter
- Share Repurchase Program: Cencora, Inc.'s Board of Directors has authorized a new $2 billion share repurchase program aimed at enhancing shareholder value through opportunistic buybacks, which is expected to positively impact the company's stock price.
- Financial Guidance Update: The company has raised its fiscal year 2026 adjusted diluted earnings per share guidance to a range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90, reflecting confidence in future performance.
- Repurchase Progress: As of May 21, 2026, the company has $382 million remaining under the previously authorized repurchase program from May 2024, indicating active utilization of market opportunities to strengthen its capital structure.
- Investor Discussion Participation: Cencora will participate in upcoming investor discussions where the updated outlook for fiscal year 2026 will be elaborated, further bolstering market confidence in the company's growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 264.750
Low
400.00
Averages
415.38
High
440.00
Current: 264.750
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora Authorizes $2 Billion Share Repurchase Program
- Share Repurchase Program: Cencora, Inc.'s Board of Directors has authorized a new $2 billion share repurchase program aimed at enhancing shareholder value through opportunistic buybacks, which is expected to positively impact the company's stock price.
- Financial Guidance Update: The company has raised its fiscal year 2026 adjusted diluted earnings per share guidance to a range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90, reflecting confidence in future performance.
- Repurchase Progress: As of May 21, 2026, the company has $382 million remaining under the previously authorized repurchase program from May 2024, indicating active utilization of market opportunities to strengthen its capital structure.
- Investor Discussion Participation: Cencora will participate in upcoming investor discussions where the updated outlook for fiscal year 2026 will be elaborated, further bolstering market confidence in the company's growth potential.
See More
Cencora Under Investigation Amid Stock Plunge
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of full-year revenue growth guidance to 4%-6%, indicating significant market challenges ahead for the company.
- Impact of Pricing Strategy: Management disclosed that manufactured price reductions resulted in a $2 billion revenue headwind during the quarter, a critical factor that directly affected the company's profitability and investor confidence.
- Stock Price Volatility: Following the earnings report, Cencora's stock plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting investor concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could further impact the company's reputation and shareholder interests.
See More
Cencora Under Investigation as Shares Plunge 17.4%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Cencora, focusing on potential violations of securities laws, particularly whether the company issued false or misleading statements that could affect investor rights.
- Earnings Miss: Cencora's Q2 2026 financial results released on May 6 revealed that the company missed consensus estimates and lowered its full-year guidance, indicating significant financial pressure on the firm.
- Revenue Loss Impact: The company claimed that manufactured price reductions represented a $2 billion revenue headwind for the quarter, raising concerns among investors about the company's future performance.
- Severe Stock Reaction: Following this news, Cencora's shares fell by 17.4% on the same day, reflecting strong market concerns regarding the company's financial health and potentially prompting more investors to seek legal recourse.
See More
Cencora Under Investigation Amid Stock Plunge Following Earnings Miss
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of its full-year revenue growth guidance to 4% to 6% from 7% to 9%.
- Impact of Price Adjustments: Management disclosed during the earnings call that manufactured list price reductions resulted in a $2 billion revenue headwind for the quarter, exacerbating investor concerns regarding the company's future performance.
- Stock Price Volatility: Following the earnings report on May 6, 2026, Cencora's stock price plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting strong market apprehension about the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could have significant implications for the company's reputation and future legal liabilities.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
Cencora Reports Q2 2026 Earnings Highlights
- Revenue Growth and Adjusted EPS: Cencora reported an adjusted EPS of $4.75 for Q2, reflecting a 7.5% growth, indicating solid operating income growth in both U.S. and International Healthcare Solutions segments, showcasing the company's robust market performance.
- Full-Year Guidance Raised: Management raised the full-year EPS guidance to a range of $17.65 to $17.90, demonstrating confidence in future profitability, despite lowering revenue growth expectations from 7%-9% to 4%-6%, primarily due to faster brand conversion rates.
- Cash Flow and Shareholder Returns: Cencora ended March with $2.2 billion in cash and plans to repurchase $1 billion worth of shares by year-end, a move aimed at enhancing shareholder returns and optimizing capital structure.
- Market Challenges and Strategic Responses: Despite challenges from manufacturer price reductions and customer concentration changes, management remains confident in maintaining operating income growth and emphasizes addressing market dynamics through digital transformation and portfolio optimization.
See More
Cencora Authorizes $2 Billion Share Repurchase Program
- Share Repurchase Program: Cencora, Inc.'s Board of Directors has authorized a new $2 billion share repurchase program aimed at enhancing shareholder value through opportunistic buybacks, which is expected to positively impact the company's stock price.
- Financial Guidance Update: The company has raised its fiscal year 2026 adjusted diluted earnings per share guidance to a range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90, reflecting confidence in future performance.
- Repurchase Progress: As of May 21, 2026, the company has $382 million remaining under the previously authorized repurchase program from May 2024, indicating active utilization of market opportunities to strengthen its capital structure.
- Investor Discussion Participation: Cencora will participate in upcoming investor discussions where the updated outlook for fiscal year 2026 will be elaborated, further bolstering market confidence in the company's growth potential.
See More
Cencora Under Investigation Amid Stock Plunge
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of full-year revenue growth guidance to 4%-6%, indicating significant market challenges ahead for the company.
- Impact of Pricing Strategy: Management disclosed that manufactured price reductions resulted in a $2 billion revenue headwind during the quarter, a critical factor that directly affected the company's profitability and investor confidence.
- Stock Price Volatility: Following the earnings report, Cencora's stock plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting investor concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could further impact the company's reputation and shareholder interests.
See More
Cencora Under Investigation as Shares Plunge 17.4%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Cencora, focusing on potential violations of securities laws, particularly whether the company issued false or misleading statements that could affect investor rights.
- Earnings Miss: Cencora's Q2 2026 financial results released on May 6 revealed that the company missed consensus estimates and lowered its full-year guidance, indicating significant financial pressure on the firm.
- Revenue Loss Impact: The company claimed that manufactured price reductions represented a $2 billion revenue headwind for the quarter, raising concerns among investors about the company's future performance.
- Severe Stock Reaction: Following this news, Cencora's shares fell by 17.4% on the same day, reflecting strong market concerns regarding the company's financial health and potentially prompting more investors to seek legal recourse.
See More
Cencora Under Investigation Amid Stock Plunge Following Earnings Miss
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of its full-year revenue growth guidance to 4% to 6% from 7% to 9%.
- Impact of Price Adjustments: Management disclosed during the earnings call that manufactured list price reductions resulted in a $2 billion revenue headwind for the quarter, exacerbating investor concerns regarding the company's future performance.
- Stock Price Volatility: Following the earnings report on May 6, 2026, Cencora's stock price plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting strong market apprehension about the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could have significant implications for the company's reputation and future legal liabilities.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
Cencora Reports Q2 2026 Earnings Highlights
- Revenue Growth and Adjusted EPS: Cencora reported an adjusted EPS of $4.75 for Q2, reflecting a 7.5% growth, indicating solid operating income growth in both U.S. and International Healthcare Solutions segments, showcasing the company's robust market performance.
- Full-Year Guidance Raised: Management raised the full-year EPS guidance to a range of $17.65 to $17.90, demonstrating confidence in future profitability, despite lowering revenue growth expectations from 7%-9% to 4%-6%, primarily due to faster brand conversion rates.
- Cash Flow and Shareholder Returns: Cencora ended March with $2.2 billion in cash and plans to repurchase $1 billion worth of shares by year-end, a move aimed at enhancing shareholder returns and optimizing capital structure.
- Market Challenges and Strategic Responses: Despite challenges from manufacturer price reductions and customer concentration changes, management remains confident in maintaining operating income growth and emphasizes addressing market dynamics through digital transformation and portfolio optimization.
See More
